Canaccord Genuity Group Issues Positive Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price

Key Points

• Canaccord Genuity raised its price target on Ascendis Pharma from $268 to $274 but maintained a Hold rating, implying 2.59% upside from the stock’s current price.
• Analyst sentiment is more positive overall: 19 analysts rate the stock Buy and two rate it Hold, for a consensus Moderate Buy rating and a $306.55 average target.
• The company’s Q3 product revenue rose 89% year over year to €366 million, led by YORVIPATH at €291 million; Ascendis also expects at least €600 million in operating cash flow for the full year.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target upped by analysts at Canaccord Genuity Group from $268.00 to $274.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a "hold" rating on the biotechnology company's stock. Canaccord Genuity Group's price objective indicates a potential upside of 2.59% from the company's current price.

Several other research firms have also recently commented on ASND. Jefferies Financial Group lowered their target price on shares of Ascendis Pharma A/S from $333.00 to $330.00 and set a "buy" rating for the company in a research note on Monday, August 31st. Wall Street Zen raised shares of Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a research report on Sunday, November 8th. Stifel Nicolaus lowered their price objective on Ascendis Pharma A/S from $328.00 to $326.00 and set a "buy" rating for the company in a report on Monday, August 31st. Bank of America cut their target price on Ascendis Pharma A/S from $306.00 to $304.00 and set a "buy" rating on the stock in a research note on Monday, August 31st. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Ascendis Pharma A/S in a research report on Tuesday, October 13th. Nineteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $306.55.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock opened at $267.07 on Friday. The firm has a fifty day moving average price of $242.58 and a 200 day moving average price of $239.65. The company has a market cap of $16.66 billion, a P/E ratio of 20.72 and a beta of 0.40. Ascendis Pharma A/S has a 12 month low of $188.07 and a 12 month high of $282.15. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. The firm had revenue of $387.22 million for the quarter, compared to analysts' expectations of $376.75 million. Sell-side analysts predict that Ascendis Pharma A/S will post 3.43 earnings per share for the current fiscal year.

Insider Activity at Ascendis Pharma A/S

In other news, SVP Mads Bodenhoff sold 3,000 shares of the company's stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares of the company's stock, valued at $810,570. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 40.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Allworth Financial LP boosted its position in shares of Ascendis Pharma A/S by 103.4% in the second quarter. Allworth Financial LP now owns 240 shares of the biotechnology company's stock worth $64,000 after buying an additional 122 shares during the period. EverSource Wealth Advisors LLC lifted its position in Ascendis Pharma A/S by 34.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company's stock worth $62,000 after buying an additional 69 shares in the last quarter. Fifth Third Bancorp lifted its position in Ascendis Pharma A/S by 48.4% in the 3rd quarter. Fifth Third Bancorp now owns 279 shares of the biotechnology company's stock worth $64,000 after buying an additional 91 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 94.9% during the 1st quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company's stock valued at $70,000 after buying an additional 148 shares during the period. Finally, IFP Advisors Inc boosted its stake in shares of Ascendis Pharma A/S by 3,491.7% during the 2nd quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company's stock valued at $115,000 after buying an additional 419 shares during the period.

Ascendis Pharma A/S News Roundup

Investors following ASND have been watching these news items:

• Positive Sentiment: Ascendis reported Q3 product revenue of €366 million, up 89% year over year, led by YORVIPATH at €291 million. The company also reported better-than-expected earnings and revenue, and said it expects at least €600 million in operating cash flow for the full year. Ascendis Pharma Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: HC Wainwright lowered its price target from $344 to $335 but kept a Buy rating, indicating continued optimism while trimming its valuation view. HC Wainwright recommendations
• Neutral Sentiment: The company granted 28,030 employee warrants, which may have a modest dilutive effect. Ascendis Pharma Grants 28,030 Employee Warrants

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.